Skip to main content
. 2014 Sep;6(9):1239–1250. doi: 10.3978/j.issn.2072-1439.2014.07.33

Figure 2.

Figure 2

(A) Meta-analysis on objective response rate among advanced NSCLC patients receiving first-line chemotherapy according to EGFR mutation status; (B) meta-analysis on 6-month PFS rate among patients receiving first-line chemotherapy according to EGFR mutation status. NSCLC, non-small-cell lung cancer; EGFR, epidermal growth factor receptor; PFS, progression-free survival; CI, confidence interval; I2, inconsistency statistic.